Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2012, Article ID 630543, 7 pages
http://dx.doi.org/10.1155/2012/630543
Review Article

Molecular Pathogenesis of Cholangiocarcinoma

Division of Gastroenterology, Azienda Ospedaliero-Universitaria “Ospedali Riuniti” Via Conca 72, 60020 Ancona, Italy

Received 28 April 2011; Accepted 23 May 2011

Academic Editor: Alberto Quaglia

Copyright © 2012 G. Fava and I. Lorenzini. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. N. Lazaridis and G. J. Gores, “Cholangiocarcinoma,” Gastroenterology, vol. 128, no. 6, pp. 1655–1667, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Patel, “Worldwide trends in mortality from biliary tract malignancies,” BMC Cancer, vol. 2, p. 10, 2002. View at Google Scholar · View at Scopus
  3. D. Alvaro, E. Crocetti, S. Ferretti, M. C. Bragazzi, and R. Capocaccia, “Descriptive epidemiology of cholangiocarcinoma in Italy,” Digestive and Liver Disease, vol. 42, no. 7, pp. 490–495, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. S. A. Khan, H. C. Thomas, B. R. Davidson, and S. D. Taylor-Robinson, “Cholangiocarcinoma,” The Lancet, vol. 366, no. 9493, pp. 1303–1314, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. G. Fava, M. Marzioni, A. Benedetti et al., “Molecular pathology of biliary tract cancers,” Cancer Letters, vol. 250, no. 2, pp. 155–167, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. D. S. Sandhu, A. M. Shire, and L. R. Roberts, “Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets,” Liver International, vol. 28, no. 1, pp. 12–27, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. I. Tischoff, C. Wittekind, and A. Tannapfel, “Role of epigenetic alterations in cholangiocarcinoma,” Journal of Hepato-Biliary-Pancreatic Surgery, vol. 13, no. 4, pp. 274–279, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. K. Okuda, Y. Nakanuma, and M. Miyazaki, “Cholangiocarcinoma: recent progress. Part 2: molecular pathology and treatment,” Journal of Gastroenterology and Hepatology, vol. 17, no. 10, pp. 1056–1063, 2002. View at Google Scholar
  9. K. N. Lazaridis, “Cholangiocarcinoma: epidemiology, risk factors and molecular pathogenesis,” in Pathophysiologiy of the Intrahepatic Biliary Epithelium, S. De Morrow, S. Glaser, G. Alpini, M. Marzioni, and G. Fava, Eds., pp. 301–313, Transworld Research Network, Kerala, India, 2008. View at Google Scholar
  10. Y. H. Shaib, H. B. El-Serag, J. A. Davila, R. Morgan, and K. A. Mcglynn, “Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study,” Gastroenterology, vol. 128, no. 3, pp. 620–626, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. J. D. Coudert and W. Held, “The role of the NKG2D receptor for tumor immunity,” Seminars in Cancer Biology, vol. 16, no. 5, pp. 333–343, 2006. View at Google Scholar
  12. E. Melum, T. H. Karlsen, E. Schrumpf et al., “Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms,” Hepatology, vol. 47, no. 1, pp. 90–96, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. Komori, H. Marusawa, T. Machimoto et al., “Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma,” Hepatology, vol. 47, no. 3, pp. 888–896, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. F. Meng, Y. Yamagiwa, Y. Ueno, and T. Patel, “Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes,” Journal of Hepatology, vol. 44, no. 6, pp. 1055–1065, 2006. View at Publisher · View at Google Scholar · View at PubMed
  15. T. Akiyama, T. Hasegawa, T. Sejima et al., “Serum and bile interleukin 6 after percutaneous transhepatic cholangio-drainage,” Hepato-Gastroenterology, vol. 45, no. 21, pp. 665–671, 1998. View at Google Scholar · View at Scopus
  16. K. Okada, Y. Shimizu, S. Nambu, K. Higuchi, and A. Watanabe, “Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line,” Journal of Gastroenterology and Hepatology, vol. 9, no. 5, pp. 462–467, 1994. View at Google Scholar
  17. L. Tadlock and T. Patel, “Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line,” Hepatology, vol. 33, no. 1, pp. 43–51, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. H. Isomoto, S. Kobayashi, N. W. Werneburg et al., “Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells,” Hepatology, vol. 42, no. 6, pp. 1329–1338, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. M. Taniai, A. Grambihler, H. Higuchi et al., “Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells,” Cancer Research, vol. 64, no. 10, pp. 3517–3524, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. H. Isomoto, J. L. Mott, S. Kobayashi et al., “Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing,” Gastroenterology, vol. 132, no. 1, pp. 384–396, 2007. View at Publisher · View at Google Scholar
  21. S. Kobayashi, N. W. Werneburg, S. F. Bronk, S. H. Kaufmann, and G. J. Gores, “Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells,” Gastroenterology, vol. 128, no. 7, pp. 2054–2065, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. B. R. A. Blechacz, R. L. Smoot, S. F. Bronk, N. W. Werneburg, A. E. Sirica, and G. J. Gores, “Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2,” Hepatology, vol. 50, no. 6, pp. 1861–1870, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. L. A. Saperstein, R. L. Jirtle, M. Farouk, H. J. Thompson, K. S. Chung, and W. C. Meyers, “Transforming growth factor-beta1 and mannose 6-phosphate/insulin-like growth factor-II receptor expression during intrahepatic bile duct hyperplasia and biliary fibrosis in the rat,” Hepatology, vol. 19, no. 2, pp. 412–417, 1994. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Miyazaki, R. Ohashi, T. Tsuji, K. Mihara, E. Gohda, and M. Namba, “Transforming growth factor-beta 1 stimulates or inhibits cell growth via down- or up-regulation of p21/Waf1,” Biochemical and Biophysical Research Communications, vol. 246, no. 3, pp. 873–880, 1998. View at Google Scholar
  25. Y. Yamagiwa and T. Patel, “Cytokine regulation of cholangiocyte growth,” in The Pathophysiology of Biliary Epithelia, G. Alpini, D. Alvaro, M. Marzioni, G. LeSage, and N. F. LaRusso, Eds., pp. 227–234, Landes Bioscience, Georgetown, Tex, USA, 2004. View at Google Scholar
  26. Y. Zen, K. Harada, M. Sasaki et al., “Intrahepatic cholangiocarcinoma escapes from growth inhibitory effect of transforming growth factor-beta1 by overexpression of cyclin D1,” Laboratory Investigation, vol. 85, no. 4, pp. 572–581, 2005. View at Publisher · View at Google Scholar · View at PubMed
  27. S. Yazumi, K. Ko, N. Watanabe et al., “Disrupted transforming growth factor-beta signaling and deregulated growth in human biliary tract cancer cells,” International Journal of Cancer, vol. 86, no. 6, pp. 782–789, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. S. C. Chuang, K. T. Lee, K. B. Tsai et al., “Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers,” World Journal of Surgery, vol. 28, no. 10, pp. 995–1000, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. X. Xu, S. Kobayashi, W. Qiao et al., “Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1843–1852, 2006. View at Publisher · View at Google Scholar · View at PubMed
  30. Y. K. Kang, W. H. Kim, and J. J. Jang, “Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma,” Human Pathology, vol. 33, no. 9, pp. 877–883, 2002. View at Publisher · View at Google Scholar · View at PubMed
  31. A. E. Sirica, G. H. Lai, K. Endo, Z. Zhang, and B. I. Yoon, “Cyclooxygenase-2 and ERBB-2 in cholangiocarcinoma: potential therapeutic targets,” Seminars in Liver Disease, vol. 22, no. 3, pp. 303–313, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. K. Endo, B. I. Yoon, C. Pairojkul, A. J. Demetris, and A. E. Sirica, “ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions,” Hepatology, vol. 36, no. 2, pp. 439–450, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. S. I. Aishima, K. I. Taguchi, K. Sugimachi, M. Shimada, K. Sugimachi, and M. Tsuneyoshi, “c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma,” Histopathology, vol. 40, no. 3, pp. 269–278, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Qiu, L. Ravi, and H. J. Kung, “Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells,” Nature, vol. 393, no. 6680, pp. 83–85, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. G. H. Lai, Z. Zhang, X. N. Shen et al., “erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer,” Gastroenterology, vol. 129, no. 6, pp. 2047–2057, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. J. R. Brown and R. N. DuBois, “COX-2: a molecular target for colorectal cancer prevention,” Journal of Clinical Oncology, vol. 23, no. 12, pp. 2840–2855, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. Z. Zhang, G. H. Lai, and A. E. Sirica, “Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation,” Hepatology, vol. 39, no. 4, pp. 1028–1037, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. J. H. Yoon, A. E. Canbay, N. W. Werneburg, S. P. Lee, and G. J. Gores, “Oxysterols induce cyclooxygenase-2 expression in cholangiocytes: implications for biliary tract carcinogenesis,” Hepatology, vol. 39, no. 3, pp. 732–738, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. W. G. Haigh and S. P. Lee, “Identification of oxysterols in human bile and pigment gallstones,” Gastroenterology, vol. 121, no. 1, pp. 118–123, 2001. View at Google Scholar · View at Scopus
  40. T. Wu, J. Leng, C. Han, and A. J. Demetris, “The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells,” Molecular Cancer Therapeutics, vol. 3, no. 3, pp. 299–307, 2004. View at Google Scholar · View at Scopus
  41. G. H. Lai, Z. Zhang, and A. E. Sirica, “Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3,” Molecular Cancer Therapeutics, vol. 2, no. 3, pp. 265–271, 2003. View at Google Scholar · View at Scopus
  42. J. R. Testa and A. Bellacosa, “AKT plays a central role in tumorigenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 20, pp. 10983–10985, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. C. Han, J. Leng, A. J. Demetris, and T. Wu, “Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest,” Cancer Research, vol. 64, no. 4, pp. 1369–1376, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Ishimura, S. F. Bronk, and G. J. Gores, “Inducible nitric oxide synthase upregulates cyclooxygenase-2 in mouse cholangiocytes promoting cell growth,” AJP—Gastrointestinal and Liver Physiology, vol. 287, no. 1, pp. G88–G95, 2004. View at Publisher · View at Google Scholar · View at PubMed
  45. M. Jaiswal, N. F. LaRusso, and G. J. Gores, “Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis,” AJP—Gastrointestinal and Liver Physiology, vol. 281, no. 3, pp. G626–G634, 2001. View at Google Scholar · View at Scopus
  46. N. Ishimura, S. F. Bronk, and G. J. Gores, “Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis,” Gastroenterology, vol. 128, no. 5, pp. 1354–1368, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Alpini, J. M. McGill, and N. F. LaRusso, “The pathobiology of biliary epithelia,” Hepatology, vol. 35, no. 5, pp. 1256–1268, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. N. J. Torok and G. J. Gores, “Apoptosis of biliary epithelial cells,” in The Pathophysiology of Biliary Epithelia, G. Alpini, D. Alvaro, M. Marzioni, G. LeSage, and N. F. LaRusso, Eds., pp. 219–226, Landes Bioscience, Georgetown, Tex, USA, 2004. View at Google Scholar
  49. D. M. Harnois, F. G. Que, A. Celli, N. F. LaRusso, and G. J. Gores, “Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line,” Hepatology, vol. 26, no. 4, pp. 884–890, 1997. View at Google Scholar · View at Scopus
  50. N. J. Torok, H. Higuchi, S. Bronk, and G. J. Gores, “Nitric oxide inhibits apoptosis downstream of cytochrome c release by nitrosylating caspase 9,” Cancer Research, vol. 62, no. 6, pp. 1648–1653, 2002. View at Google Scholar · View at Scopus
  51. H. Walczak, R. E. Miller, K. Ariail et al., “Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo,” Nature Medicine, vol. 5, no. 2, pp. 157–163, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. T. Yamanaka, K. Shiraki, K. Sugimoto et al., “Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines,” Hepatology, vol. 32, no. 3, pp. 482–490, 2000. View at Google Scholar · View at Scopus
  53. J. L. Mott, S. Kobayashi, S. F. Bronk, and G. J. Gores, “mir-29 regulates Mcl-1 protein expression and apoptosis,” Oncogene, vol. 26, no. 42, pp. 6133–6140, 2007. View at Publisher · View at Google Scholar · View at PubMed
  54. K. Cheng and J. P. Raufman, “Bile acid-induced proliferation of a human colon cancer cell line is mediated by transactivation of epidermal growth factor receptors,” Biochemical Pharmacology, vol. 70, no. 7, pp. 1035–1047, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. U. C. Nzeako, M. E. Guicciardi, J. H. Yoon, S. F. Bronk, and G. J. Gores, “COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells,” Hepatology, vol. 35, no. 3, pp. 552–559, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. S. Tanaka, K. Sugimachi, K. Shirabe, M. Shimada, and J. R. Wands, “Expression and antitumor effects of TRAIL in human cholangiocarcinoma,” Hepatology, vol. 32, no. 3, pp. 523–527, 2000. View at Google Scholar · View at Scopus
  57. E. Gaudio, P. Onori, and A. Franchitto, “Vascularization of the intrahepatic biliary tree and its role in the regulation of cholangiocyte growth,” in The Pathophysiology of Biliary Epithelia, G. Alpini, D. Alvaro, M. Marzioni, G. LeSage, and N. F. LaRusso, Eds., Landes Bioscience, Georgetown, Tex, USA, 2004. View at Google Scholar
  58. E. Gaudio, B. Barbaro, D. Alvaro et al., “Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism,” Gastroenterology, vol. 130, no. 4, pp. 1270–1282, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. K. Sugimachi, K.-I. Taguchi, S.-I. Aishima et al., “Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma,” Modern Pathology, vol. 14, no. 9, pp. 900–905, 2001. View at Publisher · View at Google Scholar · View at PubMed
  60. C. Benckert, S. Jonas, T. Cramer et al., “Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells,” Cancer Research, vol. 63, no. 5, pp. 1083–1092, 2003. View at Google Scholar
  61. L. K. Sampson, S. M. Vickers, W. Ying, and J. O. Phillips, “Tamoxifen-mediated growth inhibition of human cholangiocarcinoma,” Cancer Research, vol. 57, no. 9, pp. 1743–1749, 1997. View at Google Scholar · View at Scopus
  62. G. Pan, S. M. Vickers, A. Pickens et al., “Apoptosis and tumorigenesis in human cholangiocarcinoma cells: involvement of Fas/APO-1 (CD95) and calmodulin,” American Journal of Pathology, vol. 155, no. 1, pp. 193–203, 1999. View at Google Scholar · View at Scopus
  63. D. Alvaro, B. Barbaro, A. Franchitto et al., “Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma,” American Journal of Pathology, vol. 169, no. 3, pp. 877–888, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. A. Mancino, M. G. Mancino, S. S. Glaser et al., “Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor,” Digestive and Liver Disease, vol. 41, no. 2, pp. 156–163, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. D. Alvaro, G. Macarri, M. G. Mancino et al., “Serum and biliary insulin-like growth factor I and vascular endothelial growth factor in determining the cause of obstructive cholestasis,” Annals of Internal Medicine, vol. 147, no. 7, pp. 451–459, 2007. View at Google Scholar · View at Scopus
  66. N. Kanno, S. Glaser, U. Chowdhury et al., “Gastrin inhibits cholangiocarcinoma growth through increased apoptosis by activation of Ca2+-dependent protein kinase C-alpha,” Journal of Hepatology, vol. 34, no. 2, pp. 284–291, 2001. View at Publisher · View at Google Scholar · View at Scopus
  67. N. Kanno, G. Lesage, J. L. Phinizy, S. Glaser, H. Francis, and G. Alpini, “Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities,” Hepatology, vol. 35, no. 6, pp. 1329–1340, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. G. Fava, L. Marucci, S. Glaser et al., “Gamma-aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway,” Cancer Research, vol. 65, no. 24, pp. 11437–11446, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. G. Fava, S. De Morrow, E. Gaudio et al., “Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression,” Liver International, vol. 29, no. 7, pp. 1031–1042, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. G. Alpini, P. Invernizzi, E. Gaudio et al., “Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth,” Cancer Research, vol. 68, no. 22, pp. 9184–9193, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. S. DeMorrow, P. Onori, J. Venter et al., “Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion,” American Journal of Physiology—Cell Physiology, vol. 300, no. 5, pp. C1078–C1089, 2011. View at Publisher · View at Google Scholar · View at PubMed
  72. G. Fava, G. Alpini, C. Rychlicki et al., “Leptin enhances cholangiocarcinoma cell growth,” Cancer Research, vol. 68, no. 16, pp. 6752–6761, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. M. Marzioni, P. Invernizzi, C. Candelaresi et al., “Human cholangiocarcinoma development is associated with dysregulation of opioidergic modulation of cholangiocyte growth,” Digestive and Liver Disease, vol. 41, no. 7, pp. 523–533, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. P. Onori, C. Wise, E. Gaudio et al., “Secretin inhibits cholangiocarcinoma growth via dysregulation of the cAMP-dependent signaling mechanisms of secretin receptor,” International Journal of Cancer, vol. 127, no. 1, pp. 43–54, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. H. Francis, P. Onori, E. Gaudio et al., “H3 histamine receptor-mediated activation of protein kinase Calpha inhibits the growth of cholangiocarcinoma in vitro and in vivo,” Molecular Cancer Research, vol. 7, no. 10, pp. 1704–1713, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus